Invention Grant
- Patent Title: Prolyl hydroxylase inhibitors
-
Application No.: US17383554Application Date: 2021-07-23
-
Publication No.: US11643397B2Publication Date: 2023-05-09
- Inventor: Kevin J. Duffy , Duke M. Fitch , Jian Jin , Ronggang Liu , Antony N. Shaw , Kenneth Wiggall
- Applicant: GlaxoSmithKline LLC
- Applicant Address: US DE New Castle
- Assignee: GlaxoSmithKline LLC
- Current Assignee: GlaxoSmithKline LLC
- Current Assignee Address: US DE Wilmington
- Agent Nora L. Stein
- Main IPC: C07D239/54
- IPC: C07D239/54 ; C07D239/60 ; A61K31/515 ; C07D239/62 ; C07D401/04 ; C07D405/04 ; C07D405/10 ; C07D409/04 ; C07D409/10 ; C07D413/06 ; C07D413/10 ; C07D417/10 ; C07D239/22
Abstract:
The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I)
which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Public/Granted literature
- US20210347740A1 Prolyl Hydroxylase Inhibitors Public/Granted day:2021-11-11
Information query
